Project cooperationUpdated on 8 January 2026
Transfection-free AAV production
Head of Technology Development at ReiThera srl
Rome, Italy
About
ReiThera offers its proprietary AdAAV technology, a transfection-free AAV manufacturing platform designed to address key scalability barriers limiting the transition of gene therapies from clinical success to commercial success.
The AdAAV platform is compatible with suspension cell culture and is suited for standardized manufacturing workflows, supporting cost containment, and long-term supply reliability.
As an SME technology partner, ReiThera can contribute to collaborative projects through:
-
Transfection-free AAV manufacturing process development and optimization
-
Scale-up and GMP-oriented process design
-
Development of analytical methods and quality control strategies
-
Translational support bridging preclinical development, clinical manufacturing, and early commercial considerations
ReiThera seeks to participate in Horizon Europe consortia by providing its AdAAV platform and industrial expertise, without acting as project coordinator, supporting projects aiming to transform innovative gene therapies into viable and accessible medicinal products.
Topic
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
Type
- Partner seeks Consortium/Coordinator
Organisation
Similar opportunities
Project cooperation
process development & GMP manufacturing of viral vectors
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
Stefania Capone
Grant Projects Director at ReiThera srl
Rome, Italy
Project cooperation
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
Angelo Raggioli
Head of Technology Development at ReiThera srl
Rome, Italy
Project cooperation
Modified Vaccinia Ankara (MVA) platform for strong T-cell immune responses
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
Angelo Raggioli
Head of Technology Development at ReiThera srl
Rome, Italy